• This record comes from PubMed

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

. 2021 Jul ; 26 (7) : 560-e1103. [epub] 20210429

Language English Country Great Britain, England Media print-electronic

Document type Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid33829609

Grant support
P30 CA093373 NCI NIH HHS - United States

LESSONS LEARNED: The combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more vascular endothelial growth factor (VEGF)-targeted therapies. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. BACKGROUND: Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors. METHODS: TRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 RESULTS: A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. CONCLUSION: The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.

See more in PubMed

Choueiri TK, Michaelson MD, Posadas EM et al. An open label phase Ib dose escalation study of TRC105 (anti‐endoglin antibody) with axitinib in patients with metastatic renal cell carcinoma. The Oncologist 2019;24:202–210. PubMed PMC

Dorff TB, Longmate JA, Pal SK et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer: Bevacizumab and TRC105 in Renal Cancer. Cancer 2017;123:4566–4573. PubMed PMC

Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011;146:873–887. PubMed

Seon BK, Haba A, Matsuno F et al. Endoglin‐targeted cancer therapy. Curr Drug Deliv 2011;8, 135–143. PubMed PMC

Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378:1931–1939. PubMed

Rosen LS, Gordon MS, Robert F et al. Endoglin for targeted cancer treatment. Curr Oncol Rep 2014;16:365. PubMed

Sánchez‐Elsner T, Botella LM, Velasco B et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor‐β pathways. J Biol Chem 2002;277:43799–43808. PubMed

Li DY, Sorensen LK, Brooke BS et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534–1537. PubMed

Duarte CW, Murray K, Lucas FL et al. Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev 2014;23:117–125. PubMed PMC

Lenato G, Guanti G. Hereditary haemorrhagic telangiectasia (HHT): Genetic and molecular aspects. Curr Pharm Des 2006;12:1173–1193. PubMed

Kumar S, Ghellal A, Li C et al. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856–861. PubMed

Duff SE, Li C, Garland JM et al. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J 2003;17:984–992. PubMed

Saad R, Elgohary Y, Memari E et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 2005;36:955–961. PubMed

Yao Y, Kubota T, Takeuchi H et al. Prognostic significance of microvessel density determined by an anti‐CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti‐CD31 monoclonal antibody. Neuropathology 2005;25:201–206. PubMed

Ding S, Li C, Lin S et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006;37:861–866. PubMed

Erdem O, Taskiran C, Onan MA et al. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol 2006;103:1007–1011. PubMed

Kyzas PA, Agnantis NJ, Stefanou D. Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch 2006;448:768–775. PubMed

Marioni G, Marino F, Giacomelli L et al. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol 2006;126: 633–639. PubMed

Taskiran C, Erdem O, Onan A et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 2006;16:1789–1793. PubMed

Yang L, Lu W, Huang G et al. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 2006;6:110. PubMed PMC

El‐Gohary YM, Silverman JF, Olson PR et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007;127:572–579. PubMed

Rubatt JM, Darcy KM, Hutson A et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol 2009;112:469–474. PubMed

Dallas NA, Samuel S, Xia L et al. Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008;14:1931–1937. PubMed

Bauman TM, Huang W, Lee MH et al. Neovascularity as a prognostic marker in renal cell carcinoma. Hum Pathol 2016;57:98–105. PubMed

Nolan‐Stevaux O, Zhong W, Culp S et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti‐endoglin antibodies. PLoS One 2012;7:e50920. PubMed PMC

Rosen LS, Hurwitz HI, Wong MK et al. A phase I FIRST‐IN‐HUMAN STUDY of TRC105 (anti‐endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012;18:4820–4829. PubMed PMC

Voss, M. H. et al. The DART study: Results from the dose‐escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma. Clin Cancer Res 2017;23:3557–3565. PubMed

Grivas PD, Daignault S, Tagawa ST et al. Double‐blind, randomized, phase II trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2014;120:692–701. PubMed

Liu Y, Tian H, Blobe GC et al. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs 2014;32:851–859. PubMed PMC

Find record

Citation metrics

Archiving options